ReviewJournal of cancer research and clinical oncology2015
Cervical cancer stem cells: opportunities and challenges.
Review in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Molecular markers for cervical cancer prognosis: a prognostic model using stemness-related lncRNAs and functional analysis of EMX2OS.BMC cancer · 2026Article
- Photodynamic therapy boosts the anti-proliferative activity of oxaliplatin in cervical cancer cells by regulating stemness-related genes.Medical oncology (Northwood, London, England) · 2025Article
- Linderapyrone analogue LPD-01 as a cancer treatment agent by targeting importin7.Journal of natural medicines · 2024Article
- The Effect ofAdvances in pharmacological and pharmaceutical sciences · 2023Article
- Circular RNA circ_0004488 Increases Cervical Cancer Paclitaxel Resistance via the miR-136/MEX3C Signaling Pathway.Journal of oncology · 2022Article
- Tumor budding of cervical squamous cell carcinoma: epithelial-mesenchymal transition-like cancer stem cells?PeerJ · 2022Article
- The Involvement of Natural Polyphenols in the Chemoprevention of Cervical Cancer.International journal of molecular sciences · 2021Review
- LncRNA HOTAIR promotes proliferation and inhibits apoptosis by sponging miR-214-3p in HPV16 positive cervical cancer cells.Cancer cell international · 2021Article
- Ubiquitin-conjugating enzyme E2T promotes tumor stem cell characteristics and migration of cervical cancer cells by regulating the GRP78/FAK pathway.Open life sciences · 2021Article
- CD276 (B7H3) improve cancer stem cells formation in cervical carcinoma cell lines.Translational cancer research · 2021Article
- BRM270 targets cancer stem cells and augments chemo-sensitivity in cancer.Oncology letters · 2020Review
- Recent advances in the contribution of noncoding RNAs to cisplatin resistance in cervical cancer.PeerJ · 2020Article
- Cervical cancer stem cells and other leading factors associated with cervical cancer development.Oncology letters · 2019Review
- Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer.Investigational new drugs · 2019Article
- Photodynamic therapy of cervical cancer by eradication of cervical cancer cells and cervical cancer stem cells.Oncotarget · 2019Article
- Potential role of cancer stem cells as biomarkers and therapeutic targets in cervical cancer.Cancer reports (Hoboken, N.J.) · 2019Review
- Lost expression of cell adhesion molecule 1 is associated with bladder cancer progression and recurrence and its overexpression inhibited tumor cell malignant behaviors.Oncology letters · 2019Article
- Studying the regression profiles of cervical tumours during radiotherapy treatment using a patient-specific multiscale model.Scientific reports · 2019Article
- Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer.Oncotarget · 2018Article
- Upregulation of stem cell markers ALDH1A1 and OCT4 as potential biomarkers for the early detection of cervical carcinoma.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCervical cancer remains a leading cause of cancer-related deaths in women in spite of screening and vaccination programs. The current treatment strategies including chemotherapy and surgery could only prolong the patient's survival rather than provide a permanent cure. In case of advanced cervical cancer, radical surgery remains the only option which not only affects the child-bearing ability of the patient, but also comes with a continual risk of recurrence of the disease. Hence, there is a need to develop innovative therapeutics. The cancer stem cell hypothesis states that a tumor has a hierarchical cellular structure in which only a small subpopulation, referred to as cancer stem cells (CSCs), is capable of tumorigenesis. The CSCs possess the stem-like properties of self-renewal and can differentiate into non-stem tumor cells.
resultsA large number of studies suggest that CSCs are resistant to the conventional therapies used for cancer treatment. These therapies rather enrich the proportion of CSCs in the tumor by eliminating non-stem tumor cells, thereby causing enhanced drug resistance resulting in relapse of the disease. This makes CSCs as the most likely targets for therapeutic intervention. Also, the increase in the proportion of CSCs in patient samples is associated with poor survival rate, thus highlighting their potential role as prognostic biomarker.
conclusionThe CSCs have been identified and characterized in cervical cancer cell lines, but there are hardly any reports of CSCs in cervical cancer patient samples. This review highlights the current status of research on cervical CSCs, their clinical significance and the challenges in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.